COVALIA study update: Safety Results from needle-free SARS-CoV2 DNA vaccine phase 1 trial
Posted: 21 January 2022 First needle-free SARS-CoV2 DNA vaccine tested in Australia is well tolerated No safety concerns were observed Ongoing study enrolment for booster dose Technovalia, an Australian biotech vaccine developer has announced the interim safety results…
Sophie Stocker receives grant to lead charge for precision medicine research
Posted: 20 December 2021 Dr. Sophie Stocker, a senior lecturer at the University of Sydney, has been awarded a Ramaciotti Health Investment Grant of close to $100,000 by the Clive and Vera Ramaciotti Foundations to undertake medical research for precision medicine using a…
MedTech Innovator Asia Pacific 2022 Accelerator Program – Applications now open
Posted: 13 December 2021 About MedTech Innovator Asia Pacific MedTech Innovator is the medical technology industry’s global showcase and accelerator for innovative medical device, digital health and diagnostic companies. The mission is to improve the lives of patients…
2022 ANDHealth+ cohort announced
Posted: 13 December 2021 BioMelbourne Network Member, ANDHealth, have welcomed the five companies selected for the 2022 ANDHealth+ program, Australia’s leading commercialisation program for digital health. The successful companies were announced by Dr Katie Allen, MP, Member for…
Inhaled AD-214 passes first development milestone
Posted: 13 December 2021 BioMelbourne Network Member, AdAlta Limited, the clinical stage drug discovery company developing novel therapeutic products from its i-body platform, is pleased to announce that initial testing of AD-214 in nebulisation devices has exceeded expectations.…
$5M Boost to Innovation in Australia with New Illumina Genomics Lab
Posted 2 December New laboratory opens in Melbourne Biomedical Precinct to accelerate the adoption of genomics in healthcare and agriculture in Australia. Illumina, Inc. (NASDAQ: ILMN), the global leader in genomics, today announced the opening of a new,…
Universal Biosensors Update
Posted: 1 December 2021 Below is an update from BioMelbourne Network Member Universal Biosensors. Sentia Universal Biosensors’ (UBI) development of our new Glucose, Fructose and Malic Acid biosensors for the wine industry is approaching completion with product release…
MedTech Actuator Origin Semi-Finalists announced
Posted 17 November 2021 Twenty impressive teams recently battled it out at the MedTech Actuator Origin Rapid Fire Rounds, pitching their ideas to improve and save lives through health innovation. Ten teams took out top place and are…
Florey Institute’s in-house legal counsel recognised by Association of Corporate Counsel Australia
Posted: 5 November 2021 Florey Institute of Neuroscience and Mental Health’s in-house legal counsel, Ms Charlotte Weld-Blundell, is a finalist in the Association of Corporate Counsel Australia’s corporate lawyer awards. Charlotte was recognised in the ‘New to In-House’…
Have your say on Australia’s Biotechnology Future
Posted: 5 November 2021 You’re invited to have your say on the Biotechnology Blueprint, the Australian biotechnology industry’s decadal strategy. The Biotechnology Blueprint (the Blueprint) is a shared vision for the industry, by the industry. Led by AusBiotech, and…
ANDHealth CEO Appointed as a Member of the Council of the NHMRC
Posted: 27 October 2021 BioMelbourne Network Member ANDHealth has announced that CEO and Managing Director, Bronwyn Le Grice, has been appointed by the Hon Greg Hunt, the Australian Minister for Health and Aged Care, as a Member of…
Amplia appoints leading drug developer as Oncology Clinical Advisor
Posted: 27 October 2021 Amplia Therapeutics has today announced the appointment of internationally renowned drug developer, José Iglesias M.D, as its Oncology Clinical Advisor. Click here to read today’s ASX release Dr Iglesias has over 33 years’ experience in…
